Results 81 to 90 of about 20,250 (180)

Physapubescin B From Physalis: A Food‐Derived Withanolide for Cancer Chemoprevention and Nutraceutical Development

eFood, Volume 7, Issue 4, August 2026.
Physapubescin B may interfere with multiple cancer‐associated signaling pathways by inhibiting Ras/Raf/mitogen‐activated protein kinase kinase/extracellular signal‐regulated kinase (Ras/Raf/MEK/ERK) signaling and vascular endothelial growth factor (VEGF)‐dependent angiogenesis.
Wojciech Koch, Katarzyna Stępnik, Anna Wawruszak, Estera Okoń, Agata Jarząb, Katarzyna Gaweł‐Bęben, Magdalena Michalak‐Tomczyk, Jacek Jachuła, Magdalena Zdziebło, Paweł Helon, Javad Sharifi‐Rad, Daniela Calina   +11 more
wiley   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Halofuginone induces ERK phosphorylation and synergizes with trametinib in gastric cancer cells

International Journal of Immunopathology and Pharmacology
Objective: The aim of this study was to investigate the effects of halofuginone (HF) on gastric cancer cells and whether the combination of HF and trametinib has synergistic effects.
Yuemin Sun, Peng Wang, Xiaofeng Bai, Liang Tian, Yuxin Zhong   +4 more
doaj   +1 more source

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome

Frontiers in Pediatrics
IntroductionRare pathogenic variants in the PTPN11, KRAS, SOS1 and RAF1 genes are the main molecular causes of Noonan syndrome (NS). Most are dominant gain-of-function variants that cause an overactivation of the RAS/MAPK signaling pathway leading to ...
Isabel De Brouchoven, Juan Lorand, Léon Bofferding, Arthur Sorlin, An Van Damme, Olivier Danhaive, Olivier Danhaive   +6 more
doaj   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis

International Journal of Cancer, Volume 159, Issue 3, Page 768-781, 1 August 2026.
In high‐grade serous ovarian cancer, malignant ascites frequently arise as ovarian cancer cells shed from the primary tumor and aggregate into tumorspheres, severely limiting treatment success. To date, little is known about the mechanisms governing tumorsphere endurance and metastasis within the ascites once formed.
Núria Gendrau‐Sanclemente, Agnès Figueras, Ferran Medina‐Jover, Juan A. Marín‐Jiménez, Michelle De Leeuw, Tianyu Dai, Marina Moreno‐Mosquera, Andrea Morales, Marc Guiu, Josefina Casas, José Carlos Perales, Roger R. Gomis, Francesc Viñals   +12 more
wiley   +1 more source

ATF4/SCO2 Inhibits Ferroptosis in Lung Cancer Through Activating the MAPK Signaling Pathway

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
ATF4 activates the transcription of SCO2 to increase SCO2 expression that further stimulates p38/ERK1 signals in MAPK pathway, ultimately promoting proliferation and migration while inhibiting apoptosis and ferroptosis of lung cancer cells. ABSTRACT Ferroptosis is a specific cell death form resulting from the iron‐dependent lipid peroxidation ...
Liang Yu, Sheng Zhang, Jinxi He, Bo Ma, Xuyang Song, Rui Qiu, Bo Yu   +6 more
wiley   +1 more source

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Scientific Reports
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are ...
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek   +37 more
doaj   +1 more source

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no definitive cure is currently available. As a consequence, therapeutic efforts
Raffaele Epis, Gabriele Rovetta, Giulia Ferrari, Chiara Bonfanti, Giorgia Careccia, Graziella Messina   +5 more
wiley   +1 more source

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

IJU Case Reports
Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cystectomy ...
Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya   +4 more
doaj   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source